Does the media refer more to CRDF or TARA?

In the previous week, Cardiff Oncology had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Protara Therapeutics. Cardiff Oncology's average media sentiment score of 0.63 beat Protara Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRDF or AVXL?

In the previous week, Anavex Life Sciences had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Anavex Life Sciences and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Anavex Life Sciences' score of 0.62 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CRDF or SIGA?

Cardiff Oncology currently has a consensus price target of $7.50, indicating a potential upside of 703.00%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CRDF or SIGA?

In the previous week, Cardiff Oncology had 1 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Cardiff Oncology and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.79 beat Cardiff Oncology's score of 0.63 indicating that Siga Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Siga Technologies 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CHRS or CRDF?

In the previous week, Cardiff Oncology had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Coherus Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Coherus Oncology's score of 0.56 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CGEN or CRDF?

In the previous week, Compugen had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Compugen and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Compugen's score of 0.45 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiff Oncology (CRDF) Competitors

$0.93 +0.08 (+9.19%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$0.93 0.00 (-0.43%)

As of 08:04 AM Eastern

Compare

CRDF vs. TARA, AVXL, SIGA, CHRS, and CGEN

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include Protara Therapeutics (TARA), Anavex Life Sciences (AVXL), Siga Technologies (SIGA), Coherus Oncology (CHRS), and Compugen (CGEN).

How does Cardiff Oncology compare to Protara Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Cardiff Oncology has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	108.44	-$45.85M	-$0.67	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Cardiff Oncology has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cardiff Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 703.00%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 561.21%. Given Cardiff Oncology's higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cardiff Oncology had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Protara Therapeutics. Cardiff Oncology's average media sentiment score of 0.63 beat Protara Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protara Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Protara Therapeutics' return on equity of -38.70% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Protara Therapeutics	N/A	-38.70%	-36.02%

Summary

Cardiff Oncology beats Protara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cardiff Oncology compare to Anavex Life Sciences?

Cardiff Oncology (NASDAQ:CRDF) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Anavex Life Sciences has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Anavex Life Sciences' return on equity of -32.73% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Cardiff Oncology has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 703.00%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 623.16%. Given Cardiff Oncology's higher probable upside, research analysts clearly believe Cardiff Oncology is more favorable than Anavex Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cardiff Oncology has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	108.44	-$45.85M	-$0.67	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A

In the previous week, Anavex Life Sciences had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Anavex Life Sciences and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Anavex Life Sciences' score of 0.62 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Anavex Life Sciences beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Siga Technologies?

Cardiff Oncology (NASDAQ:CRDF) and Siga Technologies (NASDAQ:SIGA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Cardiff Oncology has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Cardiff Oncology currently has a consensus price target of $7.50, indicating a potential upside of 703.00%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cardiff Oncology had 1 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Cardiff Oncology and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.79 beat Cardiff Oncology's score of 0.63 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Siga Technologies	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Siga Technologies has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	108.44	-$45.85M	-$0.67	N/A
Siga Technologies	$94.57M	2.43	$23.28M	$0.27	11.89

Siga Technologies has a net margin of 21.58% compared to Cardiff Oncology's net margin of -8,527.43%. Siga Technologies' return on equity of 10.60% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Siga Technologies	21.58%	10.60%	8.94%

Summary

Siga Technologies beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 501.85%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 703.00%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Coherus Oncology has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$46.88M	4.74	$168.02M	$1.67	0.86
Cardiff Oncology	$590K	108.44	-$45.85M	-$0.67	N/A

In the previous week, Cardiff Oncology had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Coherus Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Coherus Oncology's score of 0.56 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has a net margin of 397.30% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Coherus Oncology beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Compugen?

Compugen (NASDAQ:CGEN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Compugen had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Compugen and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.63 beat Compugen's score of 0.45 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Compugen has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.09	$35.34M	$0.37	6.43
Cardiff Oncology	$590K	108.44	-$45.85M	-$0.67	N/A

Compugen has a net margin of 47.97% compared to Cardiff Oncology's net margin of -8,527.43%. Compugen's return on equity of 47.72% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

12.2% of Compugen shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 110.08%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 703.00%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Compugen beats Cardiff Oncology on 13 of the 17 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.60M	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-1.39	7.29	280.72	24.99
Price / Sales	108.44	1,271.79	645.01	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.39	16.69	10.94	6.21
Net Income	-$45.85M	-$12.54M	$3.48B	$347.49M
7 Day Performance	14.18%	0.25%	0.80%	1.28%
1 Month Performance	-26.46%	-7.46%	-4.17%	-3.62%
1 Year Performance	-62.79%	47.08%	61.47%	18.37%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	3.8308 of 5 stars	$0.93 +9.2%	$7.50 +703.0%	-64.6%	$58.60M	$590K	N/A	20	News Coverage
TARA Protara Therapeutics	1.8537 of 5 stars	$4.04 +0.5%	$26.25 +549.8%	+29.7%	$225.94M	N/A	N/A	30	News Coverage Positive News
AVXL Anavex Life Sciences	1.7025 of 5 stars	$2.50 +4.2%	$21.33 +753.3%	-73.7%	$222.41M	N/A	N/A	40	News Coverage Earnings Report
SIGA Siga Technologies	0.7022 of 5 stars	$3.10 -0.3%	N/A	-50.3%	$222.34M	$93.78M	11.48	40	High Trading Volume
CHRS Coherus Oncology	3.2763 of 5 stars	$1.46 +3.5%	$8.67 +493.6%	+64.0%	$217.49M	$42.17M	0.87	330	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. TARA, AVXL, SIGA, CHRS, and CGEN

How does Cardiff Oncology compare to Protara Therapeutics?

Summary

How does Cardiff Oncology compare to Anavex Life Sciences?

Summary

How does Cardiff Oncology compare to Siga Technologies?

Summary

How does Cardiff Oncology compare to Coherus Oncology?

Summary

How does Cardiff Oncology compare to Compugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. TARA, AVXL, SIGA, CHRS, and CGEN

How does Cardiff Oncology compare to Protara Therapeutics?

Which has stronger earnings and valuation, CRDF or TARA?

Which has more volatility and risk, CRDF or TARA?

Do insiders & institutionals have more ownership in CRDF or TARA?

Do analysts recommend CRDF or TARA?

Does the media refer more to CRDF or TARA?

Is CRDF or TARA more profitable?

Summary

How does Cardiff Oncology compare to Anavex Life Sciences?

Is CRDF or AVXL more profitable?

Which has more volatility & risk, CRDF or AVXL?

Do insiders & institutionals hold more shares of CRDF or AVXL?

Do analysts rate CRDF or AVXL?

Which has higher earnings & valuation, CRDF or AVXL?

Does the media refer more to CRDF or AVXL?

Summary

How does Cardiff Oncology compare to Siga Technologies?

Which has more risk and volatility, CRDF or SIGA?

Do analysts rate CRDF or SIGA?

Do institutionals and insiders believe in CRDF or SIGA?

Does the media refer more to CRDF or SIGA?

Which has preferable earnings and valuation, CRDF or SIGA?

Is CRDF or SIGA more profitable?

Summary

How does Cardiff Oncology compare to Coherus Oncology?

Do institutionals & insiders believe in CHRS or CRDF?

Do analysts prefer CHRS or CRDF?

Which has more volatility & risk, CHRS or CRDF?

Which has better valuation & earnings, CHRS or CRDF?

Does the media prefer CHRS or CRDF?

Is CHRS or CRDF more profitable?

Summary

How does Cardiff Oncology compare to Compugen?

Does the media prefer CGEN or CRDF?

Which has more risk and volatility, CGEN or CRDF?

Which has higher valuation & earnings, CGEN or CRDF?

Is CGEN or CRDF more profitable?

Do insiders and institutionals believe in CGEN or CRDF?

Do analysts recommend CGEN or CRDF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools